Skip to main content
SpringerLink
Log in

Cost Considerations in the Treatment of Schizophrenia

  • Clinical Concepts
  • Cost Considerations in Treating Schizophrenia
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Summary

Schizophrenia is a poorly understood syndrome characterised by positive symptoms (hallucinations and delusions), negative symptoms (inability to become involved in and enjoy activities and relationships) and cognitive disorganisation.

Largely because of the difficulty the schizophrenic patient has in gaining and maintaining employment, this syndrome is very costly for society. New antipsychotic agents, which are more effective and better tolerated than older drugs, and programmes designed to treat schizophrenic patients in the community rather than in the hospital both offer a great deal of promise. Lengthy, expensive hospitalisations are now quite rare. In that respect, the direct costs of schizophrenia may have lessened somewhat. However, none ofthe various pharmacological and nonpharmacological treatments available have yet convincingly increased the ability of the schizophrenic patient to work.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1995; 330: 681–90

    Article  Google Scholar 

  2. Seeman MY. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986; 73: 609–17

    Article  PubMed  CAS  Google Scholar 

  3. Faraone SV, Chen WJ, Goldstein JM, et al. Gender differences in age at onset of schizophrenia. Br J Psychiatry 1994; 164: 625–9

    Article  PubMed  CAS  Google Scholar 

  4. Swazey J. Chlorpromazine in psychiatry: a study of therapeutic innovation. Cambridge, MA: MIT Press, 1974

    Google Scholar 

  5. Frankenburg FR. History of the development of antipsychotic medications. Psychiatr Clin North Am 1994; 17: 531–40

    PubMed  CAS  Google Scholar 

  6. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 32: 229–313

    PubMed  CAS  Google Scholar 

  7. Bloom FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993; 50: 224–7

    Article  PubMed  CAS  Google Scholar 

  8. Baldessarini RJ, Huston-Lyons O, Campbell A, et al. Do central anti-adrenergic actions contribute to the atypical properties of clozapine? BrJ Psychiatry 1992; 160 Suppl. 17: 12–6

    Google Scholar 

  9. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15 Suppl.1: 28–38

    Google Scholar 

  10. Van Tol HHM, Bunzow JR, Guan H-C, et al. Cloning of the gene for a human 04 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–4

    Article  PubMed  Google Scholar 

  11. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54

    Article  PubMed  CAS  Google Scholar 

  12. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. AmJ Psychiatry 1994; 151: 1409–16

    CAS  Google Scholar 

  13. Black OW, Fisher R. Mortality in DSM-IIlR schizophrenia. Schizophr Res 1992; 7: 109–16

    Article  PubMed  CAS  Google Scholar 

  14. Goldstein JM, Santangelo SL, Simpson J, et al. Gender and mortality in schizophrenia: do women act like men? Psychol Med 1993; 23: 941–8

    Article  PubMed  CAS  Google Scholar 

  15. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994; 151: 351–6

    PubMed  CAS  Google Scholar 

  16. Carone BJ, Harrow M, Westermeyer JE. Posthospital course and outcome in schizophrenia. Arch Gen Psychiatry 1991; 48: 247–53

    Article  PubMed  CAS  Google Scholar 

  17. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48: 239–46

    Article  PubMed  CAS  Google Scholar 

  18. Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52: 29–41

    Article  PubMed  CAS  Google Scholar 

  19. Lysaker P, Bell M. Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand 1995; 91: 205–8

    Article  PubMed  CAS  Google Scholar 

  20. King OJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157: 799–811

    Article  PubMed  CAS  Google Scholar 

  21. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477–99

    PubMed  CAS  Google Scholar 

  22. Farkas MD, Rogers ES, Thurer S. Rehabilitation outcome of long-term hospital patients left behind by deinstitutionalization. Hosp Community Psychiatry 1987; 38: 864–70

    PubMed  CAS  Google Scholar 

  23. Marrone J, Balzell A, Gold M. Employment supports for people with mental illness. Psychiatr Serv 1995; 46: 707–11

    PubMed  CAS  Google Scholar 

  24. Fadden G, Bebbington P, Kuipers L. The burden of care: the impact of functional psychiatric illness on the patient’s family. Br J Psychiatry 1987; 150: 285–92

    Article  PubMed  CAS  Google Scholar 

  25. Budson RD. The psychiatric halfway house. A handbook of theory and practice. Pittsburgh: University of Pittsburgh Press, 1978

    Google Scholar 

  26. Rennie TAC. Follow-up study of five hundred patients with schizophrenia admitted to the hospital from 1913 to 1923. Arch Neurol Psychiatry 1939; 42: 877–91

    Article  Google Scholar 

  27. Fein R. Economics of mental illness. New York: Basic Books, 1958

    Book  Google Scholar 

  28. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Arch Gen Psychiatry 1985; 42: 537–43

    Article  PubMed  CAS  Google Scholar 

  29. Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental illness: 1985 report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse, and Mental Health Administration, U.S. Department of Health and Human Services. San Francisco, CA: Institute for Health & Aging, University of California, 1990

    Google Scholar 

  30. Smith K, Shah A, Wright K, et al. The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995; 166: 9–18

    Article  PubMed  CAS  Google Scholar 

  31. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993; 16: 413–23

    PubMed  CAS  Google Scholar 

  32. Reed SK, Hennessy KD, Babigian HM. Setting capitation rates for comprehensive care of persons with disabling mental illness. Psychiatr Serv 1995; 46: 127–9

    PubMed  CAS  Google Scholar 

  33. Engelhardt OM, Freedman N, Glick BS, et al. Prevention of psychiatric hospitalization with use of psychopharmacological agents. JAMA 1960; 173: 147–9

    Article  CAS  Google Scholar 

  34. Soumerai SB, McLaughlin TJ, Ross-Degnan O, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650–5

    Article  PubMed  CAS  Google Scholar 

  35. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162: 43–8

    Article  PubMed  CAS  Google Scholar 

  36. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717–25

    Article  PubMed  CAS  Google Scholar 

  37. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  38. Lindenmayer J-P, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14: 201–4

    Article  PubMed  CAS  Google Scholar 

  39. Miller DO, Perry PJ, Cadoret RJ, et al. Clozapine’s effects on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 8–15

    Article  PubMed  CAS  Google Scholar 

  40. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72

    Article  PubMed  Google Scholar 

  41. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapineinduced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7

    Article  PubMed  CAS  Google Scholar 

  42. Krupp AP, Barnes P. Clozapine-associated agranulocytosis: risk and etiology. Br J Psychiatry 1992; 160 Suppl.17: 38–40

    Google Scholar 

  43. Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalization rates among clozapine-treated patients. A prospecti ve costbenefit analysis. Ann Clin Psychiatry 1992; 4: 247–50

    Article  Google Scholar 

  44. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8

    PubMed  CAS  Google Scholar 

  45. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 3: 917–26

    Google Scholar 

  46. Marder SR, Meibach Sc. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  47. Kassirer JP, Angell M. The Journal’s policy on cost-effectiveness analyses. N Engl J Med 1994; 331: 669–70

    Article  PubMed  CAS  Google Scholar 

  48. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994; 89 Suppl.380: 27–32

    Article  Google Scholar 

  49. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145–9

    PubMed  CAS  Google Scholar 

  50. Meltzer HY, Bernett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7

    PubMed  CAS  Google Scholar 

  51. Anthony WA. Psychiatric rehabilitation: key issues and future policy. Health Aff 1992; 11: 164–71

    Article  CAS  Google Scholar 

  52. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49: 206–15

    Article  PubMed  CAS  Google Scholar 

  53. Wing J. Schizophrenia. In: Watts FN, Bennett DH, editors. Theory and practice of psychiatric rehabilitation. Chichester: John Wiley & Sons Ltd, 1983: 45–63

    Google Scholar 

  54. Stein LI, Test MA. Alternative to mental hospital treatment: I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392–7

    Article  PubMed  CAS  Google Scholar 

  55. Weisbrod B, Test MA, Stein LI. Alternative to mental hospital treatment: II. Economic cost benefit analysis. Arch Gen Psychiatry 1980; 37: 400–5

    Article  PubMed  CAS  Google Scholar 

  56. McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull 1991; 17: 375–88

    PubMed  CAS  Google Scholar 

  57. Rosenheck R, Neale M, Neale M, et al. Multisite experimental cost study of extensive psychiatric community care. Schizophr Bull 1995; 21: 129–40

    PubMed  CAS  Google Scholar 

  58. Quinlivan R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv 1995; 46: 365–71

    PubMed  CAS  Google Scholar 

  59. Olfson M. Assertive community treatment: an evaluation ofthe experimental evidence. Hosp Community Psychiatry 1990; 41: 634–41

    PubMed  CAS  Google Scholar 

  60. Rossler W, Loffler W, Flitkenheuer B, et al. Does case management reduce the rehospitalization rate? Acta Psychiatr Scand 1992; 86: 445–9

    Article  PubMed  CAS  Google Scholar 

  61. Curtis JL, Millman EJ, Streuning E, et al. Effect of case management on rehospitalization and utilization of ambulatory care services. Hosp Community Psychiatry 1992; 43: 895–9

    PubMed  CAS  Google Scholar 

  62. Tyrer P, Morgan J, Van Hom E, et al. A randomised controlled study of close monitoring of vulnerable psychiatric patients. Lancet 1995; 345: 756–9

    Article  PubMed  CAS  Google Scholar 

  63. Goldberg D. Cost-effectiveness studies in the treatment of schizophrenia: a review. Schizophr Bull 1991; 17: 453–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. McLean Hospital, Belmont and Consolidated Department of Psychiatry, Harvard Medical School, 115 Mill Street, Belmont, Boston, Massachusetts, USA

    Frances R. Frankenburg & James D. Hegarty

Authors
  1. Frances R. Frankenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James D. Hegarty
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frankenburg, F.R., Hegarty, J.D. Cost Considerations in the Treatment of Schizophrenia. CNS Drugs 5, 75–82 (1996). https://doi.org/10.2165/00023210-199605010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199605010-00006

Keywords

Search

Navigation